SR One Capital Management, LP holds a concentrated book of 15 stocks worth $1.0B as of Q2 2026 (disclosed Aug 12, 2026, a ~43-day 13F lag). This quarter they opened Avalyn Pharma Inc. Their largest long position is Veradermics Inc at 28% of the equity book.
Top-heavy: concentrated book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
90% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Other tracked managers holding the same core names as SR One Capital Management, LP
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | 15 / 15 | $622.0M |
| Ken Griffin | 14 / 15 | $317.9M |
| UBS Group AG | 14 / 15 | $255.8M |
| MORGAN STANLEY | 14 / 15 | $245.0M |
| JPMORGAN CHASE & CO | 14 / 15 | $182.2M |
| NORTHERN TRUST CORP | 14 / 15 | $152.7M |
| CITIGROUP INC | 14 / 15 | $12.9M |
| FMR LLC | 13 / 15 | $965.1M |
Ranked by how many of SR One Capital Management, LP's top 15 disclosed names each fund also holds: a cross-fund conviction signal from the latest 13F of every tracked manager.
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Veradermics, Inc. Common Stock | $295.3M | 2.40M | 28.4% | —Held | |
| 2 | Zenas BioPharma, Inc Common Stock | $127.9M | 5.04M | 12.3% | —Held | |
| 3 | CRISPR Therapeutics AG Common Shares | $111.2M | 2.04M | 10.7% | —Held | |
| 4 | Avalyn Pharma, Inc Common Stock | $108.9M | 3.31M | 10.5% | ▲New New position | |
| 5 | Design Therapeutics, Inc. Common Stock | $94.4M | 6.53M | 9.1% | —Held | |
| 6 | Odyssey Therapeutics, Inc. Common Stock | $71.0M | 3.79M | 6.8% | ▲New New position | |
| 7 | Alumis Inc. Common Stock | $55.2M | 1.96M | 5.3% | —Held | |
| 8 | ORIC Pharmaceuticals, Inc. Common Stock | $50.0M | 4.62M | 4.8% | ▲+2.2% Added · +100K sh | |
| 9 | Mineralys Therapeutics Inc. Common Stock | $42.2M | 1.56M | 4.1% | —Held | |
| 10 | ARS Pharmaceuticals, Inc. Common Stock | $32.1M | 4.01M | 3.1% | —Held | |
| 11 | Mobia Medical, Inc Common Stock | $26.6M | 1.99M | 2.6% | ▲New New position | |
| 12 | Nkarta, Inc. Common Stock | $9.4M | 3.33M | 0.9% | —Held | |
| 13 | Oculis Holding AG Ordinary Shares | $8.9M | 641.0K | 0.9% | —Held | |
| 14 | Ultragenyx Pharmaceutical Inc. Common Stock | $4.6M | 137.8K | 0.4% | —Held | |
| 15 | enGene Holdings Inc. Common Shares | $1.3M | 747.8K | 0.1% | —Held |
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1910264/holdings"
Use Arkolith to show SR ONE CAPITAL MANAGEMENT, LP's latest holdings, largest changes, and filing provenance.
As-of date vs the date the SEC received each filing
| Quarter | As of | Filed | Positions | Value | Form |
|---|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | Aug 12, 2026 | 15 | $1.0B | 13F-HR |
| Q1 2026 | Mar 31, 2026 | May 14, 2026 | 14 | $915.4M | 13F-HR |
| Q4 2025 | Nov 12, 2025 | Nov 12, 2025 | 12 | $691.4M | 13F-HR |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly, filed up to 45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.